{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:16:23Z","timestamp":1789042583234,"version":"build-2803163510"},"reference-count":126,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Osteosarcoma clinical presentation, treatment tolerance, and treatment delivery differ across the age spectrum. Adult cohorts are more heterogeneous, with higher proportions of axial and secondary osteosarcoma and greater variation in comorbidity and treatment intensity. Furthermore, emerging genomic studies suggest age-associated differences in tumor complexity and stress-response pathways, whereas direct age-stratified epigenomic and immune-microenvironment data remain limited. These molecular observations are hypothesis-generating and data currently do not support age-specific treatment selection. This narrative review summarizes clinical and biological evidence across age groups, distinguishes prognostic associations from predictive treatment effects, and identifies major confounders and evidence gaps. The available evidence supports age-inclusive prospective trials that model age explicitly, incorporate biomarker-stratified analyses, and report delivered dose intensity, toxicity, and host factors.<\/jats:p>","DOI":"10.3390\/jcm15187017","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:38:39Z","timestamp":1789040319000},"page":"7017","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteosarcoma Across the Age Spectrum: Why Outcomes Diverge and Trials Must Adapt"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-641X","authenticated-orcid":false,"given":"Samantha H.","family":"Collins","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6408-9109","authenticated-orcid":false,"given":"Igor","family":"Matushansky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New Horizons in the Treatment of Osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/cncr.34163","article-title":"Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017","volume":"128","author":"Cole","year":"2022","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","article-title":"The epidemiology of osteosarcoma","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jjco\/hyaf094","article-title":"Osteosarcoma in Japan: Report from the bone and soft tissue tumor registry 2006\u20132022","volume":"55","author":"Ogura","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.22.02767","article-title":"Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols","volume":"41","author":"Bielack","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2340\/ao.v65.45405","article-title":"Increasing survival disparity between children, adolescents, and young adults with osteosarcoma or Ewing sarcoma of bone from 1990 to 2024: A population-based cohort study","volume":"65","author":"Rostgaard","year":"2026","journal-title":"Acta Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kim, C., Davis, L.E., Albert, C.M., Samuels, B., Roberts, J.L., and Wagner, M.J. (2023). Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?. Cancers, 15.","DOI":"10.3390\/cancers15205044"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.5858\/2007-131-942-SAIPDO","article-title":"Sarcomas arising in Paget disease of bone: A clinicopathologic analysis of 70 cases","volume":"131","author":"Deyrup","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13577149977631","article-title":"Paget\u2019s Osteosarcoma\u2014No Cure in Sight","volume":"3","author":"Shaylor","year":"1999","journal-title":"Sarcoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00432-009-0690-5","article-title":"Age as a prognostic factor for patients with osteosarcoma: An analysis of 438 patients","volume":"136","author":"Harting","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0959-8049(02)00037-0","article-title":"Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup","volume":"38","author":"Hauben","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Boyland, R., Amin, S., Shostrom, V., Zheng, C., Allison, J., and Lin, C. (2025). Comparison of overall survival of adult and pediatric osteosarcoma patients using the national cancer database. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13496-3"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1002\/cncr.27414","article-title":"Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children\u2019s Oncology Group","volume":"118","author":"Janeway","year":"2012","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e13876","DOI":"10.1200\/JCO.2025.43.16_suppl.e13876","article-title":"Impact of time to treatment initiation on overall survival for patients with osteosarcoma: A SEER database analysis","volume":"43","author":"Han","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e30135","DOI":"10.1002\/pbc.30135","article-title":"Determinants and impact of diagnostic interval in bone sarcomas: A retrospective cohort study","volume":"70","author":"Sasi","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00003086-200204000-00008","article-title":"Primary osteosarcoma in adults older than 40 years","volume":"397","author":"Carsi","year":"2002","journal-title":"Clin. Orthop."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Breden, S., Beischl, S., Hinterwimmer, F., Consalvo, S., Knebel, C., von Eisenhart-Rothe, R., Burgkart, R., and Lenze, U. (2025). Surgical Margin Analysis in Osteosarcoma: Impact on Survival and Local Control. Cancers, 17.","DOI":"10.3390\/cancers17152581"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1002\/cncr.26037","article-title":"Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma","volume":"117","author":"Ciernik","year":"2011","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2017.02.030","article-title":"Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis","volume":"98","author":"Demizu","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2021.01.029","article-title":"The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma","volume":"159","author":"Seidensaal","year":"2021","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1302\/0301-620X.96B4.32629","article-title":"The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas","volume":"96-B","author":"Igarashi","year":"2014","journal-title":"Bone Jt. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Qu, G., Ma, S., Li, Z., Tian, Z., Wang, J., Wang, X., Zhang, P., Niu, X., and Yao, W. (2026). Prognostic Analysis of Endoprosthetic Reconstruction Versus Biological Reconstruction in the Treatment of Extremity Osteosarcoma. Cancers, 18.","DOI":"10.3390\/cancers18040610"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2106\/JBJS.18.00893","article-title":"Long-Term Clinical Outcomes of Intercalary Allograft Reconstruction for Lower-Extremity Bone Tumors","volume":"102","author":"Sanders","year":"2020","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s11999-015-4644-8","article-title":"What Are the Long-term Results of MUTARS\u00ae Modular Endoprostheses for Reconstruction of Tumor Resection of the Distal Femur and Proximal Tibia?","volume":"475","author":"Bus","year":"2017","journal-title":"Clin. Orthop."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.avsg.2026.03.040","article-title":"Femoral-Axis Oncovascular Reconstruction in Thigh Sarcomas: A Structured Narrative Review of Decision-Making, Techniques, and Outcomes","volume":"129","author":"Marzano","year":"2026","journal-title":"Ann. Vasc. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jso.70194","article-title":"Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis","volume":"133","author":"Delgado","year":"2026","journal-title":"J. Surg. Oncol."},{"key":"ref_28","first-page":"e99434","article-title":"Age Matters: A Systematic Review of Limb-Salvage Surgery Outcomes in Pediatric Versus Adult Osteosarcoma","volume":"17","author":"Alharbi","year":"2025","journal-title":"Cureus"},{"key":"ref_29","unstructured":"NCCN (2026, July 22). Guidelines Detail. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1418."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.1987.5.1.21","article-title":"Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial","volume":"5","author":"Eilber","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1200\/JCO.2024.42.16_suppl.11521","article-title":"Feasibility and tolerance of high-dose methotrexate (HDMTX) in older patients with osteosarcoma","volume":"42","author":"Norman","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_32","first-page":"e23512","article-title":"Clinical characteristics and prognostic factors for survival in metastatic osteosarcoma, a 2004-2021 retrospective analysis of cases in SEER","volume":"43","author":"Mohsin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5301\/tj.5000696","article-title":"EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma","volume":"104","author":"Ferrari","year":"2018","journal-title":"Tumori"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/OP.23.00591","article-title":"Receipt of Guideline-Concordant Care is Associated with Improved Survival in Patients with Osteosarcoma in California: A Population-Based Analysis","volume":"20","author":"Keegan","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaccao.2022.11.016","article-title":"Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients","volume":"5","author":"Heemelaar","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdq609","article-title":"Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper","volume":"22","author":"Aapro","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1158\/1078-0432.CCR-20-2682","article-title":"Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors","volume":"26","author":"Trendowski","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of Cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e089783","DOI":"10.1136\/bmjopen-2024-089783","article-title":"Rate of decline in kidney function with age: A systematic review","volume":"14","author":"Guppy","year":"2024","journal-title":"BMJ Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","article-title":"Methotrexate: Clinical pharmacology, current status and therapeutic guidelines","volume":"4","author":"Bleyer","year":"1977","journal-title":"Cancer Treat. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and Managing Toxicities of High-Dose Methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"ref_45","first-page":"851","article-title":"Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy","volume":"10","author":"Bacci","year":"2003","journal-title":"Oncol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cam4.1898","article-title":"Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults","volume":"8","author":"Wippel","year":"2019","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1200\/JCO.2000.18.24.4028","article-title":"Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup","volume":"18","author":"Lewis","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ejca.2011.09.012","article-title":"Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup","volume":"48","author":"McTiernan","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): An open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","article-title":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients with Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","volume":"33","author":"Bielack","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized Double-Blind Phase II Study of Regorafenib in Patients with Metastatic Osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Tirtei, E., Campello, A., Sciannameo, V., Asaftei, S.D., Meazza, C., Sironi, G., Longhi, A., Ibrahim, T., Tamburini, A., and Coccoli, L. (2024). Prolonged 14-day continuous infusion of high-dose ifosfamide for patients with relapsed and refractory high-grade osteosarcoma: A retrospective multicentre cohort study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12498-x"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e29458","DOI":"10.1002\/pbc.29458","article-title":"Impact of locus of care on outcomes in adolescents and young adults with osteosarcoma and Ewing sarcoma treated at pediatric versus adult cancer centers: An IMPACT cohort study","volume":"69","author":"Mortazavi","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jamaoncol.2024.4381","article-title":"Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults with Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial","volume":"10","author":"Gaspar","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","article-title":"Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): A multicentre, open-label, multicohort, phase 1\/2 study","volume":"22","author":"Gaspar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2024.42.16_suppl.1534","article-title":"Impact of age on clinical trial availability for AYAs with cancer: A time-trend analysis","volume":"42","author":"Mittal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/323643a0","article-title":"A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma","volume":"323","author":"Friend","year":"1986","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10032","DOI":"10.1200\/JCO.2026.44.16_suppl.10032","article-title":"Comprehensive genomic landscape of osteosarcoma: Systematic review and analysis of 1,058 patients across 20 studies with therapeutic implications from the Fight Osteosarcoma Through European Research (FOSTER) Consortium","volume":"44","author":"Palmerini","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","article-title":"Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma","volume":"6","author":"Mirabello","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"100283","DOI":"10.1016\/j.labinv.2023.100283","article-title":"Osteosarcomas with Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous","volume":"104","author":"Difilippo","year":"2024","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cell.2024.12.005","article-title":"Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution","volume":"188","author":"Trevers","year":"2025","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"djv101","DOI":"10.1093\/jnci\/djv101","article-title":"Germline TP53 Variants and Susceptibility to Osteosarcoma","volume":"107","author":"Mirabello","year":"2015","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1200\/JCO.2024.42.16_suppl.11525","article-title":"Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R\/R) osteosarcoma","volume":"42","author":"Avutu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10147-024-02673-2","article-title":"Age-related genomic alterations and chemotherapy sensitivity in osteosarcoma: Insights from cancer genome profiling analyses","volume":"30","author":"Outani","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1200\/JCO.2025.43.16_suppl.10005","article-title":"Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma","volume":"43","author":"Forrest","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccell.2015.06.001","article-title":"MYC Is a Major Determinant of Mitotic Cell Fate","volume":"28","author":"Topham","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.chembiol.2025.07.004","article-title":"Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers","volume":"32","author":"Yang","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-025-01219-7","article-title":"Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial","volume":"10","author":"Tian","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zou, C., Huang, R., Lin, T., Wang, Y., Tu, J., Zhang, L., Wang, B., Huang, J., Zhao, Z., and Xie, X. (2024). Age-dependent molecular variations in osteosarcoma: Implications for precision oncology across pediatric, adolescent, and adult patients. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1382276"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101266","DOI":"10.1016\/j.neo.2025.101266","article-title":"Dual CDK4\/6\u2013PI3K\/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma","volume":"72","author":"Barghi","year":"2026","journal-title":"Neoplasia"},{"key":"ref_76","unstructured":"National Cancer Institute (NCI) (2026, July 26). A Feasibility and Randomized Phase 2\/3 Study of the VEGFR2\/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma. clinicaltrials.gov, Clinical trial registration NCT05691478, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05691478."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"104710","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients with TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/1078-0432.CCR-23-2959","article-title":"Phase I\/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcS\u00e9-ESMART Trial","volume":"30","author":"Gatz","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e033009","DOI":"10.1136\/bmjopen-2019-033009","article-title":"Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: The WISTERIA trial protocol","volume":"10","author":"Kong","year":"2020","journal-title":"BMJ Open"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1038\/s41467-021-27291-8","article-title":"Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma","volume":"12","author":"Zoumpoulidou","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.celrep.2015.02.059","article-title":"Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining","volume":"10","author":"Cook","year":"2015","journal-title":"Cell Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1101\/gad.288282.116","article-title":"RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1","volume":"30","author":"Manickavinayaham","year":"2016","journal-title":"Genes Dev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1101\/gad.1917310","article-title":"Loss of pRB causes centromere dysfunction and chromosomal instability","volume":"24","author":"Manning","year":"2010","journal-title":"Genes Dev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10015","DOI":"10.1200\/JCO.2026.44.16_suppl.10015","article-title":"Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results","volume":"44","author":"Forrest","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_88","unstructured":"Janeway, K.A. (2026, July 26). Phase II Trial of Olaparib in Combination with Ceralasertib in Patients with Recurrent Osteosarcoma. clinicaltrials.gov, Clinical trial registration NCT04417062, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04417062."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1038\/s41467-022-34689-5","article-title":"Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e2200334","DOI":"10.1200\/PO.22.00334","article-title":"Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma","volume":"7","author":"Marinoff","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41413-018-0009-8","article-title":"Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma","volume":"6","author":"Chen","year":"2018","journal-title":"Bone Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41467-026-69725-1","article-title":"The N-Myc MB0-MBI region interacts specifically and dynamically with the N-lobe of Aurora kinase A","volume":"17","author":"Hultman","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.21873\/anticanres.15115","article-title":"Combination of CDK4\/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease","volume":"41","author":"Oshiro","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Assi, T., Watson, S., Samra, B., Rassy, E., Le Cesne, A., Italiano, A., and Mir, O. (2021). Targeting the VEGF Pathway in Osteosarcoma. Cells, 10.","DOI":"10.3390\/cells10051240"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1002\/cncr.26116","article-title":"Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma","volume":"117","author":"Yang","year":"2011","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Zheng, B., Zhou, C., Qu, G., Ren, C., Yan, P., Guo, W., and Yue, B. (2020). VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.543562"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/0008-5472.CAN-05-4422","article-title":"MET overexpression turns human primary osteoblasts into osteosarcomas","volume":"66","author":"Avnet","year":"2006","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","article-title":"Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma","volume":"7","author":"Chen","year":"2014","journal-title":"Cell Rep."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Rathore, R., and Van Tine, B.A. (2021). Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061182"},{"key":"ref_100","first-page":"1099","article-title":"Biology and pathogenesis of human osteosarcoma","volume":"19","author":"Fernandes","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-015-1918-y","article-title":"Bone microenvironment signals in osteosarcoma development","volume":"72","author":"Alfranca","year":"2015","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Kondratowski, S., Cohen, D., Deyell, R.J., Sandhu, A., and Bush, J.W. (2024). Immunohistochemical study of histone protein 3 modification in pediatric osteosarcoma identifies reduced H3K27me3 as a marker of poor treatment response. PLoS ONE, 19.","DOI":"10.1101\/2023.09.13.23295510"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Twenhafel, L., Moreno, D., Punt, T., Kinney, M., and Ryznar, R. (2023). Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review. Cells, 12.","DOI":"10.3390\/cells12121595"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/2159-8290.CD-25-0237","article-title":"Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities","volume":"16","author":"Clugston","year":"2026","journal-title":"Cancer Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41568-025-00868-x","article-title":"Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer","volume":"25","author":"Easwaran","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2022.03.012","article-title":"Immune contexture of paediatric cancers","volume":"170","author":"Thakur","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Taylor, A.M., Sheng, J., Ng, P.K.S., Harder, J.M., Kumar, P., Ahn, J.Y., Cao, Y., Dzis, A.M., Jillette, N.L., and Goodspeed, A. (2025). Immunosuppressive Tumor Microenvironment of Osteosarcoma. Cancers, 17.","DOI":"10.3390\/cancers17132117"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Fujiwara, T., Healey, J., Ogura, K., Yoshida, A., Kondo, H., Hata, T., Kure, M., Tazawa, H., Nakata, E., and Kunisada, T. (2021). Role of Tumor-Associated Macrophages in Sarcomas. Cancers, 13.","DOI":"10.3390\/cancers13051086"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: Results from the PEMBROSARC study","volume":"119","author":"Blay","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","article-title":"Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: A rationale for treatment with macrophage activating agents","volume":"17","author":"Buddingh","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"111836","DOI":"10.18632\/oncotarget.22912","article-title":"Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8\/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1","volume":"8","author":"Palmerini","year":"2017","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/2767-9764.CRC-25-0086","article-title":"Preclinical Evaluation of Folate Receptor-\u03b1 Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma","volume":"5","author":"Choe","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-24-2335","article-title":"LRRC15-CAR T Cells for the Treatment of Osteosarcoma","volume":"32","author":"Tuladhar","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-024-03642-4","article-title":"Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity","volume":"73","author":"Cao","year":"2024","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Feinberg, D., Uppin, V., Eid, S., Fritz, C., Hitomi, M., Radhakrishnan, A., Klatt, K., Choi, S.H., Myers, J.T., and Bhatt, A. (2026). Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma. BMC Med., 24.","DOI":"10.1186\/s12916-026-04729-8"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40364-025-00800-3","article-title":"A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor","volume":"13","author":"Shan","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1038\/s41388-025-03605-8","article-title":"Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma","volume":"44","author":"Esaki","year":"2025","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11507","DOI":"10.1200\/JCO.2024.42.16_suppl.11507","article-title":"ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma","volume":"42","author":"Xie","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Nakano, K. (2023). The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316823"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e2023216118","DOI":"10.1073\/pnas.2023216118","article-title":"Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis","volume":"118","author":"Huang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1038\/s41467-024-55164-3","article-title":"Aging-induced immune microenvironment remodeling fosters melanoma in male mice via \u03b3\u03b417-Neutrophil-CD8 axis","volume":"15","author":"Duan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13402-026-01162-0","article-title":"Aging reshapes the osteosarcoma ecosystem through immune dysfunction and tumor cell reprogramming","volume":"49","author":"Shen","year":"2026","journal-title":"Cell. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:51:03Z","timestamp":1789041063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":126,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187017"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187017","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}